Baseline demographics of trial participants
| Placebo | Danirixin | |
| Participants | 5 | 14 |
| Age, years | 62±6 | 65±7 |
| Male/female | 2/3 | 6/8 |
| White/Caucasian/European | 5 | 14 |
| Current smoker, % | 2043 | 4320 |
| Smoking history, pack-years | 48±13 | 44±19 |
| Body mass index, kg·m−2 | 30.9 | 27.1 |
| FEV1, L | 2.49±0.64 | 1.94±0.71 |
| FEV1, % predicted | 79.1±7.5 | 69.5±18.4 |
| FVC, L | 4.07±1.16 | 3.34±1.17 |
| FEV1/FVC | 0.62±0.08 | 0.59±0.08 |
| CAT score | 17.0±1.00 | 17.3±5.97 |
| Medications | ||
| Long-acting muscarinic antagonist | 3 (60) | 9 (64) |
| Short-acting β2-agonist | 4 (80) | 8 (57) |
| Inhaled corticosteroid | 3 (60) | 6 (43) |
| Long-acting β2-agonist | 3 (60) | 9 (64) |
| Systemic corticosteroid | 0 | 1 (7) |
| Anti-infectives | 0 | 1 (7) |
Data are presented as n, mean±sd or n (%), unless otherwise stated. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; CAT: COPD Assessment Test.